FBRX

Investor Moves

Name	Value	Action	Change	Price	Current Price
Ken GriffinCitadel Advisors $-6.0K ExitQ3 2024 $6k -- $54.78
Jim SimonsRenaissance Technologies $-71.6K ExitQ3 2024 $72k -- $54.78

Insider Trades

Name	Value	Action	Price	Current Price
Riley Antony ACHIEF FINANCIAL OFFICER $255k9.7k shares BuyDec 30, 2025 $26.33 $54.78
Riley Antony ACHIEF FINANCIAL OFFICER $125k22.5k shares BuyNov 21, 2024 $5.55 $54.78

Trade FBRX

About Forte Biosciences, Inc.

Forte Biosciences, Inc. is a U.S.-based biopharmaceutical company currently in its clinical development phase. The firm's key initiative involves advancing the FB-102 program, which is designed to tackle a variety of autoimmune conditions, notably vitiligo and alopecia areata. Their main offices are situated in Dallas, Texas.

CEO: Paul A. Wagner
IPO Date: Apr 13, 2017

Market Data

Open: $17.84
High: $18.57
Low: $17.65
Volume: 170.4K
Avg Volume: 300.6K
52W High: $35.80
52W Low: $9.10

Valuation

Market Cap: $247.9M
Enterprise Value: $189.6M
Dividend Yield: 0.00%

Financials

Free Cash Flow: -$51M
Revenue: $0
Net Income: -$69.4M
Cash: $77M
Debt: $0